A vaccine against H5N1 avian influenza has been engineered and tested by researchers at the University of Pittsburgh's Center for Vaccine Research and the pharmaceutical company Novavax Inc, in Rockville,
Md (Bright RA et al. PLoS ONE. 2008;3:e1501).
The vaccine, which encodes genes for 3 influenza viral proteins,
uses a viruslike particle that lacks genetic information to reproduce,
making it safer than other avian flu vaccines that are partially developed from live viruses.
Hampton T. Avian Flu Vaccine. JAMA. 2008;299(9):1008. doi:10.1001/jama.299.9.1008-c